Rapid intracranial response to osimertinib in a patient with epidermal growth factor receptor T790M-positive adenocarcinoma of the lung

Oncology Research and Treatment

Volumn 39, Issue 7-8, 2016, Pages 461-463

  Reichegger, Hermann ^a   Jochum, Wolfram ^a   Förbs, Diana ^a   Hader, Claudia ^a   Früh, Martin ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

AZD9291; EGFR mutation; Intracranial; Lung cancer; Osimertinib; Response; T790M

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; OSIMERTINIB; PEMETREXED; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CHROMOSOME DELETION; EXON; FEMALE; GAMMA KNIFE RADIOSURGERY; GENE MUTATION; HUMAN; HUMAN TISSUE; LOCAL THERAPY; LUNG ADENOCARCINOMA; LUNG BIOPSY; MUTATIONAL ANALYSIS; STEROID THERAPY; TREATMENT RESPONSE; ADENOCARCINOMA; BRAIN NEOPLASMS; GENETICS; LUNG NEOPLASMS; POINT MUTATION; SECONDARY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; PIPERAZINES; POINT MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84975114098     PISSN: 22965270     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000446759     Document Type: Article

References (12)

1. Yu Ha, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240-2247
2. Piotrowska Z, Sequist L. Epidermal growth factor receptor-mutant lung cancer: New drugs, new resistance mechanisms, and future treatment options. Cancer J 2015; 21,371-377
3. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046-1061
4. Finlay MR, Anderton M, Ashton S, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem 2014; 57: 8249-8267
5. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372: 1689-1699
6. Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015; 372: 1700-1709
7. Park SJ, Kim HT, Lee DH, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 2012; 77: 556-560
8. Ballard P, et al Preclinical activity of AZD9291 in-EGFR-mutant NSCLC brain metastases J Thorac Oncol 2015 10(9, Suppl2): S300, abstract Mini 10.12
9. Hata A, Katakami N, Yoshioka H, et al. Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI. J Thorac Oncol 2015; 10: 1553-1559
10. Kuiper JL, Heideman DA, Thunnissen E, et al. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer 2014; 85: 19-24
11. Hata A, Katakami N, Yoshioka H, et al. Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: Poorer prognosis associated with T790M-negative status and leptomeningeal metastases. Anticancer Res 2015; 35: 1025-1031
12. Ohashi K, Maruvka YE, Michor F, Pao E. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013; 31: 1070-1080